SmithKline Beecham's drug ReQuip (ropinirole) has received approval for marketing from the UK licensing authority for the treatment of Parkinson's disease. This is the world's first approval for ReQuip, the company points out. Approval applications have also been filed in the USA, Canada, France and Italy.
Commenting on the news, SB Pharmaceuticals, Europe, chairman Bradley Wilson expressed particular pleasure at the broad labelling claim (for the treatment of idiopathic Parkinson's in early stages, alone or in combination with low-dose L-dopa) that has been approved, enabling many Parkinson's sufferers, including those in the early stages of the disease, to benefit from this new product.
A UK launch is planned very shortly, and a company spokesman told the Marketletter that ReQuip would be priced comparably with other newer dopaminergic agonists. This means an average yearly maintenance cost of between L1,000 and L1,500 ($1,559-$2,338).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze